SCHEDULE: Zeo Scientifix: Ian Bothwell Boosts Stake to 40.2%

Sentiment:

Beneficial Ownership Filing (Schedule 13D Amendment)


Ian Bothwell, CEO and CFO of Zeo Scientifix, Inc., has increased his beneficial ownership and voting power to 40.2% through stock options and restricted shares.

Summary

  • Ian Bothwell, CEO, CFO, and Director of Zeo Scientifix, Inc., has amended his Schedule 13D filing to reflect an increase in his beneficial ownership and voting power.
  • As of May 15, 2026, Bothwell beneficially owns 1,195,094 shares of common stock, representing 14.7% of the class.
  • This common stock holding includes 87,500 restricted shares vesting on July 14, 2026, 187,500 shares issuable from warrants, and 180,000 shares issuable from options.
  • Additionally, Bothwell holds 50 shares of Series C Preferred Stock, which grants him an additional 25.5% of the total voting power.
  • Consequently, Bothwell's aggregate voting power in Zeo Scientifix, Inc. now stands at 40.2%.
  • The transactions triggering this amendment include the grant of 55,000 stock options on May 8, 2025, and the grant of 175,000 restricted shares on January 14, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive due to the significant increase in ownership by the CEO/CFO, indicating strong internal conviction. However, the high concentration of voting power introduces a degree of governance risk.

Positives

  • Increased beneficial ownership and voting power by a key executive (CEO/CFO) to 40.2%, indicating strong alignment with company performance.
  • Acquisition of shares through equity incentive plans (options and restricted stock) suggests management's confidence in future growth.
  • The filing confirms no immediate plans for further acquisition or disposition of shares, suggesting a stable ownership structure in the short term.

Negatives

  • Concentration of voting power in a single individual could raise concerns about corporate governance and potential conflicts of interest for minority shareholders.
  • The filing does not provide details on the company's financial performance or operational updates, limiting a full assessment of the situation.

Risks

  • Potential for future actions by the controlling shareholder that may not align with the interests of all shareholders.
  • Lack of disclosure regarding the specific terms and vesting schedules of all options and warrants could obscure the full extent of potential dilution or future share issuances.

Future Outlook

The Reporting Person has no definite plan to acquire or dispose of additional shares but may do so in the future. The board of directors may also issue additional equity awards to the Reporting Person from time to time.

Management Comments

  • The Reporting Person has no definite plan to acquire or dispose of additional shares of the Issuer's common stock in open market or private transactions, but may do so in the future, subject to compliance with the Exchange Act and the rules and regulations thereunder.
  • While there is no definite plan to issue additional shares of the Issuer's common stock to the Reporting Person under one or more of the Issuer's equity incentive plans, the board of directors or a committee thereof may determine to issue awards of shares of common stock under such plans to the Reporting Person from time to time in the future.

Industry Context

StockSavvy.ai notes that significant increases in beneficial ownership by a company's CEO and CFO, particularly through equity awards, often signal strong internal confidence in the company's future prospects. However, such concentration of control warrants careful monitoring by other investors.

Stakeholder Impact

  • Shareholders: Increased control by CEO/CFO may lead to decisions prioritizing long-term vision but could also raise concerns about minority shareholder influence.
  • Employees: Continued issuance of equity awards to management signals a focus on performance-based incentives.
  • Creditors: No immediate impact indicated, as the filing focuses on ownership structure rather than financial distress or restructuring.

Next Steps

  • The Reporting Person may acquire or dispose of additional shares in the future.
  • The board of directors may issue additional equity awards to the Reporting Person.

Key Dates

DateDescription
2018-08-16Original Schedule 13D filing date.
2021-08-20Amendment No. 1 filing date.
2025-01-07Amendment No. 2 filing date.
2025-05-08Grant of 55,000 stock options under the Issuer's 2021 Equity Incentive Plan.
2026-01-14Grant of 175,000 restricted shares under the Plan.
2026-03-16Date as of which shares of common stock outstanding were reported by the Issuer.
2026-03-17Date of Issuer's Quarterly Report on Form 10-Q filing.
2026-07-14Vesting date for 87,500 restricted shares.
2026-05-15Filing date of Amendment No. 3 to Schedule 13D.

Recommendation

hold

The filing indicates a significant increase in control by the CEO/CFO, which can be a positive sign of management's commitment. However, without further information on the company's financial performance or strategic direction, a 'hold' recommendation is prudent. Investors should monitor future disclosures for operational and financial updates to assess the long-term implications of this concentrated ownership.

Keywords

Schedule 13D, Zeo Scientifix, Ian Bothwell, Beneficial Ownership, Voting Power, Common Stock, Preferred Stock, Stock Options, Restricted Stock, Equity Incentive Plan, SEC Filing, Amendment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.